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Abstract
Background: Substituted 1,3,4-oxadiazoles are of considerable pharmaceutical interest. 2,5-Substituted diphenyl-
1,3,4-oxadiazoles are associated with diverse biological activities by the virtue of -N = C-O- grouping. In the view of
wide range of biological properties associated with 1,3,4-oxadiazole, we have synthesized substituted derivatives of
1,3,4-oxadiazole (XIII-XXII), a versatile hydrophobic molecule possessing preliminary CNS properties, with the hope
to potentiate the biological activities with lesser or limited amount of toxicities.
Method: The synthesis was based on ester substitution of substituted benzohydrazide in presence of hydrazine
hydrate followed by cyclization in presence of phosphorus oxychloride. All the synthesized compounds were
evaluated for their potential CNS depressant activities. Statistical analysis of the anticonvulsant, antidepressant, and
antianxiety activity of the synthesized compounds on animals was evaluated using one-way analysis of variance
(ANOVA).
Results: Two compounds 5-(4-nitrophenyl)-2-(4-chlorophenyl)-1,3,4-oxadiazole (XIV) and 5-(4-nitrophenyl)-2-(4-
nitrophenyl)-1,3,4-oxadiazole (XV) were found to be the most promising compounds of the series in
antidepressant, anticonvulsant and antianxiety activity with no neurotoxicity when compared with standard.
Conclusions: Among the synthesized compounds, it was found that incorporation of electron withdrawing group
at C2 and C5 position of the oxadiazole ring led to high degree of pharmacological activity. Thus compounds 5-(4-
nitrophenyl)-2-(4-chlorophenyl)-1,3,4-oxadiazole (XIV) and 5-(4-nitrophenyl)-2-(4-nitrophenyl)-1,3,4-oxadiazole (XV)
showed excellent CNS depressant activities. The result of the present investigation may encourage us to develop
and/or improve similar other related compounds and it may be assumed that further modifications may produce
compounds of better activity with lesser side effects.
Background
Epilepsy is one of the most common neurological disor-
ders responsible for substantial morbidity and mortality.
It is a chronic neurological disorder characterized by
paroxysmal, excessive, and hyper-synchronous neuronal
activity in the brain affecting around 1-2% of the world
population [1,2]. 75-80% of the epileptic patients may be
provided with adequate seizure control with the help of
conventional antiepileptic drugs. Despite the develop-
ment of several new anticonvulsants, the treatments of
epilepsy still remain inadequate. However, over 30% of
people with epilepsy do not have seizure control even
with the best available medications [3].
Most people with epilepsy have a normal emotional
and cognitive life, however neurobehavioral problems
can be found in a large number of patients. Higher rates
of psychopathology have been reported in people with
epilepsy compared with the general population and in
people with chronic non-neurological disorders [4].
Depression and anxiety are the most frequent types of
psychiatric disorders identified in patients with epilepsy
[5]. There are numerous studies reporting that the
severity of anxiety and depression in epileptic patients is
higher than normal controls [6-8].
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provided the original work is properly cited.The comorbidity of major depressive disorder or anxi-
ety is associated with medical, psychiatric, and social
problems. A bidirectional relationship between epilepsy
a n dd e p r e s s i o ni ss u p p o s e dt oe x i s ta n ds t u d i e ss u g -
gested that depression and epilepsy may share common
pathogenic mechanisms and the occurrence of one may
facilitate the development of the other and vice versa
[9,10]. Multiple factors are implicated in the develop-
ment of depression in epilepsy including clinical (seizure
frequency, seizure type or foci, epilepsy duration, age at
onset, antiepileptic drugs) and psychosocial ones (life
stressors, employment, marital status, quality of life)
[11]. Here we have selected an in-vivo efficacy approach
using maximal electroshock seizure (MES) model, spon-
taneous motor activity using actophotometer and ele-
vated plus maze model. Benzodiazepines (BZDs) are the
most frequently prescribed synthetic drugs for variety of
conditions particularly anxiety, depression, epilepsy, and
insomnia. But these psychoneural drugs have many side
effects including addictive potential and frequent devel-
opment of tolerance. BZDs have limited utility for long-
term treatment. Therefore our strategy was to find
drugs which are effective in all these models and are




Although various methods have been reported for the
synthesis of oxadiazole derivatives [12] but these meth-
ods requires high reaction temperature, long reaction,
time and expensive reagents. In present described
experimental conditions the heterocyclization reaction
reached completion with a relative simple operation giv-
ing high yield (65-95%) at shorter time (1.5-3.0 h) com-
pared to the other reported cyclization methods for
1,3,4-oxadiazole ring. The synthetic route of the
designed 1,3,4-oxadiazole derivatives 2,5-substituted
diphenyl-1,3,4-oxadiazole (XIII-XXII)w a so u t l i n e di n
Scheme 1. The possible mechanism of the final step
involved in formation of target compounds was shown
in Scheme 2. The presence of electron donating groups
(-NH2, -OH) decreases the yield of the final compound
(50-75%) with low reaction time (1.5-2.0 h) whereas the
presence of electron withdrawing groups (-NO2, -Cl,
-Br) increases the yield of the final compound thereby
increasing the reaction time (2.5-3.0 h). The structures
of the compounds were assigned on the basis of elemen-
tal analysis, IR,
1H NMR, and mass spectra. The struc-
tures of newly synthesized compounds were confirmed
by spectral and analytical data.
In general, the IR spectra of synthesized compounds
showed a C = N stretching band around 1533-1684 cm
-
1, C = O absorption band at around 1010-1091 cm
-1,
and C-O-C absorption band at around 1239-1282 cm
-1
indicating formation of the 1,3,4-oxadiazole ring. In
1H
NMR spectra, the signals of respective protons of newly
synthesized compounds showed the peaks for -NH,
-OH, and Ar-H near δ 3.8-4.9, 4.3-5.6, and 6.52-8.61,
respectively. Further evidence for the formation of 2,5-
substituted diphenyl-1,3,4-oxadiazole was obtained by
recording the mass spectra. The general mass fragmen-
tation pattern for the compound XIII showed the mole-
cular ion peak at 272.69 which is in conformity with the
molecular formula C14H9ClN2O2 (Scheme 3). Both
analytical and spectral data (IR,
1HN M R ,a n dm a s s )o f
all the synthesized compounds were in full agreement
with the proposed structures.
Pharmacology
Among the compounds synthesized (XIII-XXII), few
compounds were selected (XIII-XVII) and evaluated for
CNS depressant activities such as antidepressant, antic-
onvulsant, antianxiety, and neurotoxicity activity. The
pharmacological data indicated that among all the com-
pounds being screened, compounds XIV and XV
showed highly significant anticonvulsant activity (***p ≤
0.001) and compound XVI showed less significant activ-
ity when compared to the standard (Table 1 and Figure
1). The % potency showing the mean convulsive thresh-
old of the synthesized compounds was shown in Figure
2. In antidepressant screening, compounds XIV, XV,
and XVII decreased the locomotor activity significantly
(***p ≤ 0.001) whereas, compounds XVI (**p ≤ 0.01) and
XIII (*p ≤ 0 . 0 5 )d i dn o ts h o w e das i g n i f i c a n tr e d u c t i o n
in the locomotor activity when compared to standard
fluoxetine (Table 2 and Figure 3). In antianxiety screen-
ing, the number of entries and the mean time spent in
open arm has been shown in (Table 3, Figures 4 and 5)
and compounds, XIII and XV significantly increases the
t i m es p e n ti no p e na r mt h u sshowing higher activity
when compared to the standard diazepam. Whereas
another remarkable point is that compound having nitro
group (electron withdrawing groups) at both position 2
and 5 of the 1,3,4-oxadiazole ring, i.e., 5-(4-nitrophe-
nyl)-2-(4-nitrophenyl)-1,3,4-oxadiazole (XV) exhibited
greater anticonvulsant, antidepressant, and antianxiety
activity as compared to the other compounds of the ser-
ies. Whereas compound 5-(4-nitrophenyl)-2-(4-chloro-
phenyl)-1,3,4-oxadiazole (XIV) showed highly significant
anticonvulsant and antidepressant activity but less sig-
nificant antianxiety activity. In the neurotoxicity screen,
all the compounds being screened passed the neurotoxi-
city testing, i.e., not showing neurological deficit (Table
4). From the overall result it is evident that compound
XIV and XV could be identified as the most biologically
active member within this study with good anticonvul-
sant, antidepressant, and antianxiety activity.
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This preliminary investigation showed the cyclization of
-NH-NH2 group of benzohydrazide in presence of car-
boxylic group of benzoic acid into 1,3,4-oxadiazole with
the objective to develop molecules with excellent yield
and less reaction time. Addition of -NH2, -OH group as
substituents enhances the yield of the prepared com-
pounds. Among the synthesized compounds, those with
electron withdrawing substituents: 5-(4-nitrophenyl)-2-
(4-chlorophenyl)-1,3,4-oxadiazole (XIV) and 5-(4-nitro-
phenyl)-2-(4-nitrophenyl)-1,3,4-oxadiazole (XV) showed
excellent anticonvulsant activity, antidepressant, and
antianxiety activity with no neurotoxicity. The result of
the present investigation may encourage us to develop
and/or improve similar other related compounds and it
may be assumed that further modifications may produce
compounds of better activity with less side effects.
Experimental
Chemical synthesis
All the chemicals and reagents were obtained from
Sigma (Germany) and CDH (India) and were recrystal-
lized/redistilled as necessary. Melting points were deter-
mined by open capillary tube method and are
uncorrected. Purity of the compounds were checked on
thin layer chromatography (TLC) plates precoated with
silica gel G using solvent system ethyl acetate: petro-
leum ether (1) (3:7 v/v) and benzene: methanol (2) (2:1
Table 1 Anticonvulsant activity of synthesized compounds
Number Compound Dose (mg kg
-1) Hind limb extensor (mean ± S.E.M) Hind limb convulsion (mean ± S.E.M) % Potency
1. Control 30 27.50 ± 0.42 6.5 ± 0.47 -
2. Standard 30 15.25 ± 0.17 6.25 ± 0.30 -
3. XIII 30 11.50 ± 0.15** 8.16 ± 0.30 130.672
4. XIV 30 17.33 ± 0.33*** 24.33 ± 0.42** 389.28
5. XV 30 16.83 ± 0.20* 25.83 ± 0.54*** 413.28
6. XVI 30 15.83 ± 0.27* 10.83 ± 0.30*** 173.28
7. XVII 30 11.00 ± 0.30 7.33 ± 0.33 117.32
Values are mean ± SEM of six animals in each group. Statistical significance versus standard (***p ≤ 0.001, **p ≤ 0.01, *p ≤ 0.05)
Figure 1 Anticonvulsant activity of synthesized compounds at the dose (30 mg kg
-1, p.o.) in female albino mice for single
administration.
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and UV light. IR spectra were recorded using KBr on a
FTIR Shimadzu 8400S IR spectrophotometer (Japan). A
JEOL AL300 FTNMR 300 MHz spectrometer was used
to acquire
1H NMR spectra with DMSO as solvent and
tetra methyl silane (TMS) as internal standard. Chemical
shift values are expressed in δ ppm. Mass spectra were
obtained with a VG70-70H mass spectrometer. Elemen-
tal analyses were carried out with a Perkin Elmer model
240-C apparatus. The results of the elemental analysis
(C, H, N) are within ± 0.4% of the calculated amounts.
General procedure for the synthesis of 2,5-substituted
diphenyl-1,3,4-oxadiazoles
Step 1: Synthesis of substituted ethyl benzoate (V-VIII):
Compounds (V-VIII) was synthesized by refluxing a
m i x t u r eo fs u b s t i t u t e db e n z o i ca c i d( I - I V )( 0 . 0 5 8 7m o l )
with absolute ethanol (12 ml) in presence of conc. sul-
phuric acid (0.5 ml) for 5 h at 40-50°C. Excess of alcohol
was distilled off and allowed to cool in ice bath. Reaction
was monitored by TLC. The residue thus obtained was
separated and washed with water and recrystallized with
ethanol [13]. The physico-chemical data of the synthe-
sized compounds (V-VIII) are given in Table 5.
V: IR (KBr, cm
-1): 3581 (O-H stretch), 3040 (Ar-H
stretch), 1661 (C = O stretch), 1170 (C-O stretch);
1H
NMR (300 MHz-DMSO-d6-ppm) δ: 7.78 (d, 2H, Ar-H),
6.84 (d, 2H, Ar-H), 5.2 (s, 1H, OH), 4.19 (m, 2H, CH2),
1.30 (m, 3H, CH3); MS (EI) m/z 166.08 [M
+].
VI: IR (KBr, cm
-1): 3048 (Ar-H stretch), 1651 (C = O
stretch), 1192 (C-O stretch), 1550 (C-NO2 stretch);
1H
NMR (300 MHz-DMSO-d6-ppm) δ: 8.34 (d, 2H, Ar-H),
8.27 (m, 2H, Ar-H), 4.26 (m, 1H, CH2), 1.32 (m, 1H,
CH3); MS (EI) m/z 195.07 [M
+].
VII: IR (KBr, cm
-1): 3370 (N-H stretch), 3035 (Ar-H
stretch), 1643 (C = O stretch), 1214 (C-O stretch);
1H
NMR (300 MHz-DMSO-d6-ppm) δ: 7.75 (d, 2H, Ar-H),
6.51 (d, 2H, Ar-H), 4.35 (m, 1H, CH2), 3.97 (s, 1H,
NH), 1.28 (m, 3H, CH3); MS (EI) m/z 165.03 [M
+].
VIII: IR (KBr, cm
-1): 30443 (Ar-H stretch), 1668 (C =
O stretch), 1243 (C-O stretch), 748 (C-Cl stretch);
1H
NMR (300 MHz-DMSO-d6-ppm) δ: 7.94 (d, 2H, Ar-H),
7.35 (m, 2H, Ar-H), 4.27 (m, 2H, CH2), 1.26 (m, 2H,
CH3); MS (EI) m/z 184.01 [M
+].
Step 2: Synthesis of substituted benzohydrazide (IX-
XII):
Figure 2 %Potency of synthesized compounds at the dose (30 mg kg
-1, p.o.) in female albino mice for single administration. All the
values were expressed as mean convulsive threshold.
Table 2 Antidepressant activity of synthesized
compounds
Number Compound Dose (mg
kg
-1)
0 h (mean ± S.
E.M)
1 h (mean ± S.
E.M)
1. Control 10 345.83 ± 0.27 303.21 ± 0.42
2. Standard 10 411.16 ± 0.30 91.33 ± 0.21
3. XIII 10 401.50 ± 0.22* 85.16 ± 0.47*




5. XV 10 431.16 ±
0.30***
124.16 ± 0.40**
6. XVI 10 455.83 ± 0.47* 89.16 ± 0.30**




Values are mean ± SEM of six animals in each group. Statistical significance
versus standard (***p ≤ 0.001, **p ≤ 0.01, *p ≤ 0.05)
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mixture of substituted ethyl benzoate (V-VIII) (0.0602
mol) with hydrazine hydrate (5 ml) in absolute ethanol
(12 ml) for 8 h at 30-40°C. The reaction mixture was
cooled to room temperature and poured in ice with
constant stirring. Reaction was monitored by TLC. The
precipitate obtained was filtered, washed with water and
recrystallized with ethanol to give crystalline product.
The physico-chemical data of the synthesized com-
pounds (IX-XII) are given in Table 6.
IX: IR (KBr, cm
-1): 3472 (O-H stretch), 3336 (N-H
stretch), 3049 (Ar-H stretch), 1658 (amide C = O
stretch);
1H NMR (300 MHz-DMSO-d6-ppm) δ:7 . 7 9
(m, 2H, Ar-H), 6.86 (m, 2H, Ar-H), 4.2 (s, 1H, OH),
3.21 (m, 2H, CH2), 2.17 (d, 2H, NH), 1.23 (m, 3H,
CH3); MS (EI) m/z 180.01 [M
+].
X: IR (KBr, cm
-1): 3260 (N-H stretch), 3010 (Ar-H
stretch), 1664 (amide C = O stretch), 1511 (C-NO2
stretch);
1H NMR (300 MHz-DMSO-d6-ppm) δ: 8.35 (d,
2 H ,A r - H ) ,8 . 1 9( d ,2 H ,A r - H ) ,3 . 2 5( m ,2 H ,C H 2 ) ,1 . 9 0
(m, 2H, NH), 1.18 (m, 3H, CH3); MS (EI) m/z 209.05
[M
+].
XI: IR (KBr, cm
-1): 3368.71 (N-H stretch), 3030.95
(Ar-H stretch), 1642.31 (amide C = O stretch);
1H NMR
(300 MHz-DMSO-d6-ppm) δ:7 . 6 8( m ,2 H ,A r - H ) ,6 . 6 2
(d, 2H, Ar-H), 3.98 (d, 2H, NH), 3.18 (m, 2H, CH2),
1.81 (d, 2H, NH), 1.25 (m, 3H, CH3); MS (EI) m/z
179.15 [M
+].
XII: IR (KBr, cm
-1): 3279 (N-H stretch), 3047 (Ar-H),
1672 (amide C = O stretch), 727 (C-Cl stretch);
1H
NMR (300 MHz-DMSO-d6-ppm) δ: 7.84 (m, 2H, Ar-H),
7.44 (m, 2H, Ar-H), 3.26 (m, 2H, CH2), 2.35 (d, 2H,
NH), 1.17 (m, 3H, CH3); MS (EI) m/z 198.63 [M
+].
Step 3: Synthesis of 2,5-substituted diphenyl-1,3,4-
oxadiazole (XIII-XXII).
An equimolar mixture of substituted benzohydrazide
(IX-XII) (0.0054 mol) with various substituted benzoic
acids (0.0054 mol) was refluxed with phosphorus oxy-
chloride (5 ml) for 2-3 h on water bath at 100°C. Reac-
tion mixture was cooled to room temperature and
Figure 3 Antidepressant activity of synthesized compounds at the dose (10 mg kg
-1, p.o.) showing number of photocell count.
Table 3 Antianxiety activity of synthesized compounds
Number Compound Dose (mg kg
-1) Number of entries in open arms (Mean ± S.E.M) Average time spent in open arms (Mean ± S.E.M)
1. Control 10 2.10 ± 0.23 9.77 ± 0.27
2. Standard 10 12.66 ± 0.33 32.66 ± 0.33
3. XIII 10 13.33 ± 0.21*** 68.00 ± 0.36***
4. XIV 10 17.00 ± 0.36*** 62.33 ± 0.21**
5. XV 10 21.50 ± 0.42*** 76.83 ± 0.30***
6. XVI 10 8.83 ± 0.30*** 45.83 ± 0.30**
7. XVII 10 13.66 ± 0.42 52.66 ± 0.33*
Values are mean ± SEM of six animals in each group. Statistical significance versus standard (***p ≤ 0.001, **p ≤ 0.01, *p ≤ 0.05)
Singh et al. Organic and Medicinal Chemistry Letters 2012, 2:8
http://www.orgmedchemlett.com/content/2/1/8
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washed with water and further purified by recrystalliza-
tion with ethanol to give 2,5-substituted diphenyl-1,3,4-
oxadiazole. The physico-chemical data of the synthe-
sized compounds (XIII-XXII) are given in Table 7.
XIII: IR (KBr, cm
-1): 3448 (O-H stretch), 3070 (Ar-H
stretch), 2980 (C-H Ar. Stretch), 1593 (C = N stretch of
1,3,4-oxadiazole ring), 1417 (C = C ring stretching),
1275 (C-O-C stretch of 1,3,4-oxadiazole ring), 1016 (C-
O stretch of oxadiazole ring), 852 (Ar. C-Cl);
1HN M R
Figure 4 Antianxiety activity of synthesized compounds at the dose (2 mg kg
-1, p.o.) showing number of entries 5 min
-1.
Figure 5 Antianxiety activity of synthesized compounds at the dose (2 mg kg
-1, p.o.) showing time spent by mouse in open arm.
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Page 6 of 10(300 MHz-DMSO-d6-ppm) δ:7 . 3 9( d ,2 H ,A r - H ) ,7 . 3 1
(m, 2H, Ar-H), 7.28 (m, 2H, Ar-H), 6.85 (d, 2H, Ar-H),
4.4-5.6 (s, 1H, OH); MS (EI) m/z 272.02 [M
+]; Anal.
calcd. for C14H9ClN2O2 (%) C, 59.34; N, 9.52: O, 12.78.
XIV: IR (KBr, cm
-1): 3103 (Ar-H stretch), 2848 (Ar. C-
H stretch), 1604 (C = N stretch of 1,3,4-oxadiazole ring),
1527 (C = C ring stretching), 1463 (C-H Bend), 1350
(N-O Assymetric stretch of C-NO2), 1242 (C-O-C
stretch of 1,3,4-oxadiazole ring), 1010 (C-O stretch of
oxadiazole ring), 865 (C-N stretch of Ar. C-NO2); 838
(Ar. C-Cl);
1H NMR (300 MHz-DMSO-d6-ppm) δ:8 . 1 6
(d, 2H, Ar-H), 7.71 (m, 2H, Ar-H), 7.46 (d, 2H, Ar-H),
7.30 (t, 2H, Ar-H); MS (EI) m/z 301.04 [M
+]; Anal.
calcd. for C14H8ClN3O3 (%): C, 55.70; N, 12.73: O,
15.21.
XV: IR (KBr, cm
-1): 3038 (Ar-H stretch), 2941 (C-H
Ar. stretch), 1533 (C = N stretch of 1,3,4-oxadiazole
ring), 1409 (C = C ring stretching), 1359 (N-O stretch
Assymetric N-O stretch of C-NO2), 1278 (C-O-C
stretch of 1,3,4-oxadiazole ring), 1074 (C-O stretch of
oxadiazole ring);
1H NMR (300 MHz-DMSO-d6-ppm)
δ:7 . 7 9( d ,4 H ,A r - H ) ,8 . 3 2( d ,4 H ,A r - H ) ;M S( E I )m / z
312.05 [M
+]; Anal. calcd. for C14H8N4O5 (%) C, 54.21;
N, 18.03: O, 25.24.
XVI: IR (KBr, cm
-1): 3440 (O-H stretch), 3406 (N-H
stretch), 2952 (C-H Ar. stretch), 1633 (C = N stretch of
1,3,4-oxadiazole ring), 1519 (C = C ring stretching),
1340 (N-O stretch Assymetric N-O stretch of C-NO2),
1249 (C-O-C stretch of 1,3,4-oxadiazole ring), 1072 (C-
O stretch of 1,3,4-oxadiazole ring); 854 (C-N stretch of
Ar. C-NO2);
1H NMR (300 MHz-DMSO-d6-ppm) δ:
8 . 3 2( d ,2 H ,A r - H ) ,7 . 7 7( d ,2 H ,A r - H ) ,7 . 2 8( d ,2 H ,A r -
H), 6.57 (t, 2H, Ar-H), 3.8-4.2 (d, 2H, NH); MS (EI) m/z
282.03 [M
+]; Anal. calcd. for C14H10N4O3 (%) C,
61.26; N, 18.87; O, 17.24.
XVII: IR (KBr, cm
-1): 3409 (N-H stretch), 3451 (O-H
stretch), 2974 (C-H Ar. stretch), 1625 (C = N stretch of
1,3,4-oxadiazole ring), 1492 (C = C ring stretching),
1263 (C-O-C stretch of 1,3,4-oxadiazole ring), 1012 (C-
O stretch of oxadiazole ring),
1H NMR (300 MHz-
DMSO-d6-ppm) δ: 7.37 (d, 2H, Ar-H), 7.28 (m, 1H, Ar-
H ) ,6 . 9 1( m ,1 H ,A r - H ) ,6 . 7 5( m ,2 H ,A r - H ) ,6 . 6 2( m ,
1H, Ar-H), 6.47 (d, 1H, Ar-H), 4.3-5.5 (d, 1H, OH), 3.7-
4.9 (d, 2H, NH); MS (EI) m/z 252.62 [M
+]; Anal calcd.
for C14H11N3O2 (%) C, 66.35; N, 17.24: O, 10.35.
XVIII: IR (KBr, cm
-1): 3045 (Ar-H stretch), 1681 (C =
N stretch of 1,3,4-oxadiazole ring), 1591 (C = C ring
stretching), 1362 (Assymetric N-O stretch of C-NO2),
1247 (C-O-C stretch of 1,3,4-oxadiazole ring), 1087 (C-
O stretch of 1,3,4-oxadiazole ring); 854 (C-N stretch of
Ar. C-NO2);
1H NMR (300 MHz-DMSO-d6-ppm) δ:
8.61 (m, 2H, Ar-H), 7.71 (m, 2H, Ar-H), 7.57 (m, 1H,
Ar-H), 7.32 (m, 1H, Ar-H), 7.29 (m, 1H, Ar-H), 7.14 (m,
1H, Ar-H); MS (EI) m/z 344.89 [M
+]; Anal. calcd. for
C14H8BrN3O3 (%) C, 50.27; N, 12.23; O, 13.58.
XIX: IR (KBr, cm
-1): 3448 (N-H stretch), 2924 (C-H
Ar. stretch), 1685 (C = N stretch of 1,3,4-oxadiazole
ring), 1593.09 (C = C), 1091 (C-O stretch of 1,3,4-oxa-
diazole ring), 837 (Ar. C-Cl);
1H NMR (300 MHz-
DMSO-d6-ppm) δ:7 . 4 2( m ,2 H ,A r - H ) ,7 . 3 3( m ,2 H ,
Ar-H), 7.23 (m, 2H, Ar-H), 6.52 (m, 2H, Ar-H), 3.4-4.7
(m, 2H, NH); MS (EI) m/z 271.09 [M
+] ;A n a l .c a l c d .f o r
C14H10ClN3O (%): C, 62.79; N, 14.37; O, 14.89.
XX: IR (KBr, cm
-1): 3402 (N-H stretch), 3110 (O-H
stretch), 2987 (Ar. C-H stretch), 1608 (C = N stretch of
1,3,4-oxadiazole ring), 1525 (C = C ring stretching),
1350 (Assymetric N-O stretch of C-NO2), 1010 (C-O
stretch of 1,3,4-oxadiazole ring);
1H NMR (300 MHz-
DMSO-d6-ppm) δ:8 . 2 5( m ,2 H ,A r - H ) ,7 . 7 4( m ,2 H ,
Ar-H), 7.31 (m, 2H, Ar-H), 6.79 (m, 2H, Ar-H), 4.5-5.2
(s, 1H, OH); MS (EI) m/z 283.04 [M
+]; Anal calcd. for
C14H9N3O4 (%) C, 60.24; N, 15.43; O, 21.75.
XXI: IR (KBr, cm
-1): 3457 (O-H stretch), 2996 (C-H
Ar. stretch), 1632 (C = N stretch of 1,3,4-oxadiazole
ring), 1578 (C = C ring stretching), 1213 (C-O-C stretch
of 1,3,4-oxadiazole ring), 1075 (C-O stretch of 1,3,4-oxa-
diazole ring);
1H NMR (300 MHz-DMSO-d6-ppm) δ:
7.57 (m, 1H, Ar-H), 7.36 (m, 1H, Ar-H), 7.28 (m, 2H,
Table 4 Neurotoxic activity of the synthesized
compounds
Compound Dose (mg kg
-1) n Result
Std. (Phenytoin) 30 6 X
XIII 30 6 -
XIV 30 6 X
XV 30 6 X
XVI 30 6 -
XVIII 30 6 X
n, number of mice = 6; X, does not show neurotoxicity; ROA, orally; -,
neurotoxicity not checked.
Table 5 Physico-chemical data of the synthesized compounds (V-VIII)
Compound R Molecular formula Molecular weight % Yield m.p. (°C) Rf
solvent system
V 4-OH C9H10O3 166.17 56.21 108-110 0.72
a
VI 4-NO2 C9H9NO4 195.17 85.25 114-116 0.78
a
VII 4-NH2 C9H11NO2 165.19 64.28 90-92 0.83
a
VIII 4-Cl C9H9ClO2 184.62 87.16 127-129 0.76
a
aEthyl acetate: Petroleum ether (3:7 v/v);
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2H, Ar-H), 4.9-5.4 (s, 1H, OH); MS (EI) m/z 315.98 [M
+]; Anal. calcd. for C14H9BrN2O2 (%) C, 54.24; N, 8.82;
O, 10.94.
XXII: IR (KBr, cm
-1): 3051 (Ar-H stretch), 1618 (C =
N stretch of 1,3,4-oxadiazole ring), 1519 (C = C ring
stretching), 1282 (C-O-C stretch of 1,3,4-oxadiazole
ring), 1059 (C-O stretch of 1,3,4-oxadiazole ring); 849
(C-N stretch of Ar. C-NO2);
1H NMR (300 MHz-
DMSO-d6-ppm) δ:8 . 0 7( m ,2 H ,A r - H ) ,7 . 6 1( m ,2 H ,
Ar-H), 7.53 (m, 2H, Ar-H), 7.35 (m, 2H, Ar-H), 7.29 (m,
1H, Ar-H); MS (EI) m/z 267.06 [M
+]; Anal. calcd. for
C14H9N3O3 (%) C, 62.26; N, 15.17; O, 17.74.
Pharmacology
Albino mice of either sex, weighing (25-30 g) were used
for bioactivity studies. The animals were allowed food
and water ad libitum except during the experiments.
They were housed in a room at 25 ± 2°C and 50 ± 5%
relative humidity. Animals were obtained from Animal
House Facility, Meerut Institute of Engineering and
Technology, Meerut. All the test compounds and refer-
ence drug were administered orally, suspended in 1%
(w/v) carboxymethyl cellulose (CMC) suspension.
Anticonvulsant activity (MES)
The synthesized compounds were evaluated for their
anticonvulsant activity using MES method. The ani-
mals were randomly allocated into three groups (stan-
dard, control, and test) of six animals each and were
fasted for 24 h before the experiment with free access
to water. Control group received only 1% (w/v) car-
boxymethyl cellulose suspension. Standard drug phe-
nytoin was administered orally at a dose of 30 mg kg
-
1. The test compounds were administered orally at an
equimolar oral dose relative to 30 mg kg
-1 phenytoin.
Test compounds and standard drug were administered
orally as suspension in carboxymethyl cellulose in
water (1% w/v). Supramaximal electroshock of current
intensity 50 mA, 60 Hz was given for duration of 0.2 s
after the administration of test and standard drug.
The anticonvulsant activity was assessed after 30 min
of administration. The abolition of hind limb tonic
extensor spasm was recorded as a measure of anticon-
vulsant activity [14]. The results of anticonvulsant
activity were summarized in Table 1 and the graphs
for anticonvulsant activity were presented in Figures 1
and 2.
Antidepressant activity (spontaneous motor activity using
actophotometer)
The synthesized compounds were evaluated for their
antidepressant activity using actophotometer. The ani-
mals were randomly allocated into three groups (stan-
dard, control, and test) of six animals each and were
fasted for 24 h before the experiment with free access to
water. Control group received only 1% (w/v) carboxy-
methyl cellulose suspension.S t a n d a r dd r u gf l u o x e t i n e
was administered orally at a dose of 10 mg kg
-1.T h e
test compounds were administered orally at an
Table 6 Physico-chemical data of the synthesized compounds (IX-XII)
Compound R Molecular formula Molecular weight % Yield m.p. (°C) Rf
solvent system
IX 4-OH C7H8N2O2 152.1 35.96 132-134 0.74
a
X 4-NO2 C7H7N3O3 181.15 58.01 148-150 0.82
a
XI 4-NH2 C7H9N3O 151.17 29.16 142-144 0.75
a
XII 4-Cl C7H7ClN2O 170.60 53.13 156-158 0.77
a
aEthyl acetate: Petroleum ether (3:7 v/v);
Table 7 Physico-chemical data of the synthesized compounds (XIII-XXV)
Compound RR ’ Molecular formula Molecular weight % Yield m.p. (°C) Rf
solvent system
XIII 4-OH 4-Cl C14H9ClN2O2 272.69 74.11 95-97 0.78
a
XIV 4-NO2 4-Cl C14H8ClN3O3 301.68 82.22 165-167 0.75
a
XV 4-NO2 4-NO2 C14H8N4O5 312.24 95.24 127-129 0.67
a
XVI 4-NO2 4-NH2 C14H8ClN3O3 301.68 78.59 178-180 0.75
a
XVII 4-OH 4-NH2 C14H11N3O2 253.26 65.26 106-108 0.61
b
XVIII 4-NO2 2-Br C14H8BrN3O3 346.14 86.01 120-122 0.82
a
XIX 4-NH2 4-Cl C14H10ClN3O 271.7 78.06 175-177 0.55
b
XX 4-NO2 4-OH C14H9N3O4 283.24 64.79 104-107 0.66
b
XXI 4-OH 2-Br C14H9BrN2O2 317.14 52.36 102-104 0.74
b
XXII 4-NO2 H C14H9N3O3 267.24 81.79 104-106 0.81
a
aEthyl acetate: Petroleum ether (3:7 v/v)
bBenzene: Methanol (2:1 v/v).
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-1 fluoxetine.
Test compounds and standard drug were administered
orally as suspension in carboxymethyl cellulose in water
(1% w/v). In locomotor activity, the basal activity score
for all animals and after 60 min of drug treatment for
10 min was recorded [15]. The results of antidepressant
activity were summarized in Table 2 and the graph for
antidepressant activity was presented in Figure 3.
Antianxiety activity (elevated plus maze model)
The synthesized compounds were evaluated for their
antianxiety activity using actophotometer. The animals
were randomly allocated into 3 groups (standard, con-
trol, and test) of 6 animals each and were fasted for 24
h before the experiment with free access to water. Con-
trol group received only 1% (w/v) carboxymethyl cellu-
lose suspension. Standard drug diazepam was
administered orally at a dose of 2 mg kg
-1.T h et e s t
compounds were administered orally at an equimolar
oral dose relative to 2 mg kg
-1 diazepam. Test com-
pounds and standard drug were administered orally as
suspension in carboxymethyl cellulose in water (1% w/
v). The plus maze apparatus consists of two open arms
and two closed arms having an open roof, with the plus
maze elevated from the floor was used to observe anxio-
lytic behavior in animals. Each mouse was placed at the
center of the elevated plus maze with its head facing the
open arms [16]. During this, the behavior of the mouse
was recorded as:
(1) The number of entries into the open arms




The results of antianxiety activity were summarized in
Table 3 and the graphs for antianxiety activity were pre-
sented in Figures 4 and 5, respectively.
Neurotoxicity studies (rotarod animal model)
The disruptive effects on motor coordination were
assessed using the Rotarod Tread mill mouse method.
The mice were trained to stay on an accelerating
r o t a r o dt h a tr o t a t e sa t1 0r e v o l u t i o n sm i n
-1 and 3.2 cm
in diameter. Trained mice were given test compounds
in dose of 30 mg kg
-1 orally. Unimpaired mice can
easily remain on a rod rotating at this speed. Neurolo-
gical deficit, e.g., ataxia, sedation, hyperexcitability is
indicated by the inability of the mice to maintain equi-
librium on the rod for at least 1 min in each of three
concurrent trails [17]. The results of neurotoxic activ-
ity measured by rotarod animal model were summar-
ized in Table 6.
Statistical analysis
Statistical analysis of the anticonvulsant, antidepressant,
and antianxiety activity of the synthesized compounds
on animals was evaluated using a one-way analysis of
variance (ANOVA). In all the cases, post-hoc compari-
sons of the means of individual groups were performed
using Tukey’s test. Differences with ***p ≤ 0.001
between experimental groups at each point were consid-
ered statistically significant. All values were expressed as
mean ± SEM (standard error of mean). For statistical
analysis we use sigma stat 2.03 version. (Systat Software,
Inc. Point. CA, USA).
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